RVMD
TNGXA biotech headline with some actual teeth
Tango Therapeutics dropped early data from its ongoing Phase 1/2 study, and the numbers are the kind that make biotech investors sit up straighter: the vopimetostat plus daraxonrasib arm in pancreatic cancer showed a 92% objective response rate. In a disease as brutal as pancreatic ductal adenocarcinoma, that’s not just good — it’s attention-grabbing.
Why the market should care
The company also said the combo was generally well-tolerated, which matters almost as much as the response data. If a therapy looks effective but wrecks patients in the process, the party ends fast. Here, Tango is arguing the data support moving the combo into Phase 3 development in first-line MTAP-deleted pancreatic cancer.
The fine print your inner skeptic will want
A few caveats before we all start lighting cigars:
- This is still early-stage data from an ongoing trial.
- The reported group was patients with second- and third-line PDAC.
- Median PFS has not been reached yet, so the durability story is still developing.
- The combo includes Revolution Medicines’ RAS(ON) inhibitors, so this is also a reminder that biotech progress often comes with a plus-one.
Big picture
For Tango, this is the kind of clinical update that can change the vibe from “interesting pipeline” to “maybe we’ve got a real shot here.” Investors will now be watching whether the next wave of data holds up — because in biotech, early fireworks are great, but repeat fireworks are what pay the bills.